Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
Shapiro, Amy D., Ragni, Margaret V., Valentino, Leonard A., Key, Nigel S., Josephson, Neil C., Powell, Jerry S., Cheng, Gregory, Thompson, Arthur R., Goyal, Jaya, Tubridy, Karen L., Peters, Robert T., Dumont, Jennifer A., Euwart, Donald, Li, Lian, Hallén, Bengt, Gozzi, Peter, Bitonti, Alan J., Jiang, Haiyan, Luk, Alvin, Pierce, Glenn F.
Published in Blood (19.01.2012)
Published in Blood (19.01.2012)
Get full text
Journal Article
A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis
Goldstein, Michael H, Tubridy, Karen L, Agahigian, Jennifer, Furfine, Eric, Magill, Marianne, Kovalchin, Joseph, Golden, Kathryn, Zarbis-Papastoitsis, Gregory, Soong, Fiona, Salapatek, Anne Marie, Sternberg, Gary, Celniker, Abbie
Published in Eye & contact lens (01.05.2015)
Published in Eye & contact lens (01.05.2015)
Get more information
Journal Article
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
Roth, David A., Kessler, Craig M., Pasi, K. John, Rup, Bonita, Courter, Suzanne G., Tubridy, Karen L.
Published in Blood (15.12.2001)
Published in Blood (15.12.2001)
Get full text
Journal Article